| Literature DB >> 26576422 |
Małgorzata Gizińska1, Radosław Rutkowski1, Wojciech Romanowski2, Jacek Lewandowski3, Anna Straburzyńska-Lupa4.
Abstract
Whole-body cryotherapy (WBC) has been frequently used to supplement the rehabilitation of patients with rheumatoid arthritis (RA). The aim of this study was to compare the effect of WBC and traditional rehabilitation (TR) on clinical parameters and systemic levels of IL-6, TNF-α in patients with RA. The study group comprised 25 patients who were subjected to WBC (-110 °C) and 19 patients who underwent a traditional rehabilitation program. Some clinical variables and levels of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) were used to assess the outcomes. After therapy both groups exhibited similar improvement in pain, disease activity, fatigue, time of walking, and the number of steps over a distance of 50 m. Only significantly better results were observed in HAQ in TR group (p < 0.05). However, similar significant reduction in IL-6 and TNF-α level was observed. The results showed positive effects of a 2-week rehabilitation program for patients with RA regardless of the kind of the applied physical procedure.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26576422 PMCID: PMC4631852 DOI: 10.1155/2015/409174
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Baseline characteristics of the 44 patients with rheumatoid arthritis.
| Group I | Group II |
| |
|---|---|---|---|
| Age (years) | 55.9 ± 5.08 | 57.4 ± 5.3 | 0.3373 |
| BMI (kg/m2) | 25.5 ± 2.71 | 28.5 ± 4.78 | 0.0565 |
| DAS28 | 5.27 ± 1.13 | 4.97 ± 0.87 | 0.4409 |
| Disease duration (years) | 11 ± 5.37 | 10.7 ± 9.2 | 0.9058 |
| RF positive, | 17 (68) | 13 (68) | |
| Treatment | |||
| NSAID, | 18 (74.1) | 13 (68.4) | |
| DMARDs, | 25 (100) | 19 (100) | |
| Glucocorticoids, | 16 (66.7) | 16 (84.2) | |
| Prednisolone (mg/day) | 4 ± 0.85 | 3.4 ± 0.94 |
All data are expressed as mean ± SD (median; interquartile range) and percentages.
WBC: whole-body cryotherapy; TR: traditional rehabilitation; BMI: body mass index; DAS28: Disease Activity Score 28; RF: rheumatoid factor; DMARDs: disease-modifying antirheumatic drugs.
Clinical characteristics of the two groups before and after the therapy.
| Group I | Group II | Between groups | |||||
|---|---|---|---|---|---|---|---|
| Before | After |
| Before | After |
|
| |
| Severity of pain | 51.64 ± 17.82 | 40.80 ± 17.93 | 0.0006 | 64.05 ± 18.36 | 52.95 ± 16.36 | 0.0003 | 0.7581 |
| Duration of morning stiffness (min) | 44.92 ± 47.35 | 37.52 ± 47.41 | 0.0157 | 81.32 ± 71.12 | 58.68 ± 51.18 | 0.0511 | 0.7312 |
| HAQ-DI | 1.82 ± 1.18 | 1.64 ± 1.19 | 0.0035 | 2.72 ± 1.48 | 2.12 ± 1.30 | 0.0029 | 0.0116 |
| 50-m test, walk time (s) | 47.20 ± 11.39 | 41.36 ± 8.67 | 0.0001 | 56.11 ± 11.85 | 51.79 ± 9.63 | 0.0299 | 0.4205 |
| 50 m test, number of steps | 80.32 ± 15.14 | 76.20 ± 13.84 | 0.0030 | 90.79 ± 9.62 | 88.05 ± 10.08 | 0.0457 | 0.6356 |
| Severity of fatigue | 53.40 ± 18.95 | 44.20 ± 21.76 | 0.0034 | 63.11 ± 15.83 | 48.47 ± 18.85 | 0.0141 | 0.3871 |
All data are expressed as mean ± SD (median; inter quartile range). WBC: whole-body cryotherapy; TR: traditional rehabilitation; HAQ-DI: Health Assessment Questionnaire-Disability Index. p < 0.01, p < 0.05.
Biochemical parameters in 2 groups of patients before and after the therapy.
| Group I | Group II | Between groups | |||||
|---|---|---|---|---|---|---|---|
| Before | After |
| Before | After |
|
| |
| ESR (mm/h) | 25.52 ± 14.66 | 20.96 ± 11.73 | 0.0149 | 27.05 ± 13.66 | 24.47 ± 12.87 | 0.1416 | 0.3061 |
| IL-6 (pg/mL) | 17.96 ± 6.49 | 11.75 ± 7.56 | 0.0262 | 20.87 ± 5.43 | 10.21 ± 7.92 | 0.0076 | 0.1417 |
| TNF- | 11.77 ± 9.61 | 4.46 ± 3.82 | 0.0113 | 17.8 ± 19.54 | 7.22 ± 14.74 | 0.0258 | 0.8538 |
All data are expressed as mean (SD) (median; interquartile range). WBC: whole-body cryotherapy; TR: traditional rehabilitation; ESR: erythrocyte sedimentation ratio. p < 0.01, p < 0.05.